Nplate Purple Book BLA 125268

BLA number
125268
Proprietary names
Nplate
Proper names
romiplostim
Applicant
Amgen Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Nplateromiplostim351(a)250MCGFor InjectionSubcutaneousSingle-Dose VialRxLicensed2008-08-22
002Nplateromiplostim351(a)500MCGFor InjectionSubcutaneousSingle-Dose VialRxLicensed2008-08-22
003Nplateromiplostim351(a)125MCGFor InjectionSubcutaneousSingle-Dose VialRxLicensed2019-07-22

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-07-01U003Nplate351(a)RxAmgen Inc.
2021-04-01U001Nplate351(a)RxAmgen, Inc.
2021-04-01U002Nplate351(a)RxAmgen, Inc.
2021-04-01U003Nplate351(a)RxAmgen, Inc.
2020-10-01U001Nplate351(a)RxAmgen, Inc.
2020-10-01U002Nplate351(a)RxAmgen, Inc.
2020-10-01U003Nplate351(a)RxAmgen, Inc.
2020-08-01U001Nplate351(a)RxAmgen Inc.
2020-08-01U002Nplate351(a)RxAmgen Inc.
2020-08-01U003Nplate351(a)RxAmgen Inc.
2020-05-01R001Nplate351(a)RxAmgen Inc.
2020-05-01R002Nplate351(a)RxAmgen Inc.
2020-05-01R003Nplate351(a)RxAmgen Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2023-07-01003Nplate351(a)RxLicensed2019-07-22
2020-05-01001Nplate351(a)RxLicensed2008-08-22
2020-05-01002Nplate351(a)RxLicensed2008-08-22
2020-05-01003Nplate351(a)RxLicensed2019-10-17